MORF | tickerfilter.com

Fundamental analysis

24%

Profitability 25%

Dept financing 2%

Liquidity 75%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

67.57%

1 Year

85.82%

2 Year

126.24%

Key data

Stock price

$56.98

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

-$3.59

52 WEEK RANGE

$26.47 - $57.00

52 WEEK CHANGE

$97.33

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

50.225 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Praveen P. Tipirneni
Region: US
Website: morphictx.com
Employees: 100
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Morphic Holding, Inc. discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the. treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis. and fibrosis diseases. The company is also developing avß6 and avß8 to treat solid tumors.

MORF - Morphic Holding, Inc.